Last reviewed · How we verify
Naproxen Tramadol
Naproxen Tramadol is a Small molecule drug developed by Bnai Zion Medical Center. It is currently in Phase 1 development.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Naproxen Tramadol |
|---|---|
| Sponsor | Bnai Zion Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Agitation
- Nausea
- emesis
Key clinical trials
- Effect of Oral Analgesics on Post-op Pain (EARLY_PHASE1)
- Dronabinol On the Pain Experience (PHASE4)
- Pharmacogenetic-guided Choice of Post-surgery Analgesics (NA)
- Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure (PHASE2)
- Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain (PHASE2)
- Effect of Preoperative Tramadol and Naproxen Sodium on Post Operative Pain (PHASE2, PHASE3)
- OTC Naproxen and Acetaminophen Anti-Inflammatory Action in Dental Implant Patients (PHASE4)
- Post-Operative Pain Control Following Shoulder Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naproxen Tramadol CI brief — competitive landscape report
- Naproxen Tramadol updates RSS · CI watch RSS
- Bnai Zion Medical Center portfolio CI
Frequently asked questions about Naproxen Tramadol
What is Naproxen Tramadol?
Who makes Naproxen Tramadol?
What development phase is Naproxen Tramadol in?
What are the side effects of Naproxen Tramadol?
Related
- Manufacturer: Bnai Zion Medical Center — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing